

The long noncoding RNA CHROME regulates cholesterol

Nature Metabolism

1, 98-110

DOI: [10.1038/s42255-018-0004-9](https://doi.org/10.1038/s42255-018-0004-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Changes in the transcriptome profile of breast cancer cells grown as spheroids. <i>Biochemical and Biophysical Research Communications</i> , 2019, 516, 1258-1264.	1.0	8
2	The Long Non-Coding RNA Landscape of Atherosclerotic Plaques. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 735-749.	1.6	15
3	Non-coding RNAs – A primer for the laboratory scientist. <i>British Journal of Biomedical Science</i> , 2019, 76, 157-165.	1.2	21
4	Epigenetic Modification in Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1352-1365.	1.2	71
5	Mouse Models for Atherosclerosis Research – Which Is My Line?. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 46.	1.1	118
6	Multi-Omics Approaches to Study Long Non-coding RNA Function in Atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 9.	1.1	27
7	The lncRNA CHROME regulates cholesterol homeostasis. <i>Nature Reviews Cardiology</i> , 2019, 16, 71-71.	6.1	5
8	Lnc-ing microRNA activity to atheroprotection. <i>Nature Metabolism</i> , 2019, 1, 10-11.	5.1	0
9	MicroRNA-144 Silencing Protects Against Atherosclerosis in Male, but Not Female Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 412-425.	1.1	27
10	In vivo functional analysis of non-conserved human lncRNAs associated with cardiometabolic traits. <i>Nature Communications</i> , 2020, 11, 45.	5.8	69
11	Macrophage Long Non-Coding RNAs in Pathogenesis of Cardiovascular Disease. <i>Non-coding RNA</i> , 2020, 6, 28.	1.3	8
12	Atorvastatin Increases the Expression of Long Non-Coding RNAs ARSR and CHROME in Hypercholesterolemic Patients: A Pilot Study. <i>Pharmaceuticals</i> , 2020, 13, 382.	1.7	4
13	Long Non-Coding RNA Associated with Cholesterol Homeostasis and Its Involvement in Metabolic Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8337.	1.8	9
14	The Long Non-coding Road to Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2020, 22, 55.	2.0	34
15	Long Noncoding RNAs in Atherosclerosis and Vascular Injury. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2002-2017.	1.1	44
16	High Glucose Aggravates Cholesterol Accumulation in Glomerular Endothelial Cells Through the LXR α /lncRNAOR13C9/ABCA1 Regulatory Network. <i>Frontiers in Physiology</i> , 2020, 11, 552483.	1.3	9
17	Regulation of cellular sterol homeostasis by the oxygen responsive noncoding RNA lincNORS. <i>Nature Communications</i> , 2020, 11, 4755.	5.8	12
18	lncRNA kcnq1ot1 promotes lipid accumulation and accelerates atherosclerosis via functioning as a ceRNA through the miR-452-3p/HDAC3/ABCA1 axis. <i>Cell Death and Disease</i> , 2020, 11, 1043.	2.7	67

#	ARTICLE	IF	CITATIONS
19	LncRNA lncLy6C induced by microbiota metabolite butyrate promotes differentiation of Ly6Chigh to Ly6Cint/neg macrophages through lncLy6C/C/EBPβ ² /Nr4A1 axis. <i>Cell Discovery</i> , 2020, 6, 87.	3.1	18
20	The long non-coding RNA LUCAT1 is a negative feedback regulator of interferon responses in humans. <i>Nature Communications</i> , 2020, 11, 6348.	5.8	48
21	Pervasive Small RNAs in Cardiometabolic Research: Great Potential Accompanied by Biological and Technical Barriers. <i>Diabetes</i> , 2020, 69, 813-822.	0.3	3
22	Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e000062.	1.6	61
23	Nucleic Acid-Based Therapies for Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2020, 22, 10.	2.0	22
24	Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases. , 2020, 210, 107514.		87
25	Long Non-Coding RNAs Link Oxidized Low-Density Lipoprotein With the Inflammatory Response of Macrophages in Atherogenesis. <i>Frontiers in Immunology</i> , 2020, 11, 24.	2.2	24
26	Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease. <i>Circulation Research</i> , 2020, 126, 663-678.	2.0	140
27	Epigenetics in atherosclerosis: key features and therapeutic implications. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 719-721.	1.5	4
28	Significance of Selective Protein Degradation in the Development of Novel Targeted Drugs and Its Implications in Cancer Therapy. <i>Advanced Therapeutics</i> , 2020, 3, 1900210.	1.6	2
29	Role of epigenetic mechanisms regulated by enhancers and long noncoding RNAs in cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2020, 35, 234-241.	0.8	10
30	Noncoding RNAs in Vascular Diseases. <i>Circulation Research</i> , 2020, 126, 1127-1145.	2.0	81
31	The role of non-coding RNA network in atherosclerosis. <i>Life Sciences</i> , 2021, 265, 118756.	2.0	15
32	Functional non-coding RNAs in vascular diseases. <i>FEBS Journal</i> , 2021, 288, 6315-6330.	2.2	11
33	MicroRNA regulation of cholesterol metabolism. <i>Annals of the New York Academy of Sciences</i> , 2021, 1495, 55-77.	1.8	15
34	Identification of human long noncoding RNAs associated with nonalcoholic fatty liver disease and metabolic homeostasis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	23
36	Targeting Human lncRNAs for Treating Cardiometabolic Diseases. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 655-662.	1.3	2
37	The Emerging Role of Long Non-coding RNAs and Circular RNAs in Coronary Artery Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 632393.	1.1	19

#	ARTICLE	IF	CITATIONS
38	LncRNAs in Cardiomyocyte Maturation: New Window for Cardiac Regenerative Medicine. <i>Non-coding RNA</i> , 2021, 7, 20.	1.3	6
39	Novel Insights Linking lncRNAs and Metabolism With Implications for Cardiac Regeneration. <i>Frontiers in Physiology</i> , 2021, 12, 586927.	1.3	3
40	Where in the (lncRNA) World Is <i>CARMN</i> ?. <i>Circulation Research</i> , 2021, 128, 1276-1278.	2.0	3
41	Regulation of Long Non-Coding RNAs by Statins in Atherosclerosis. <i>Biomolecules</i> , 2021, 11, 623.	1.8	4
42	MicroRNAs and Circular RNAs in Lipoprotein Metabolism. <i>Current Atherosclerosis Reports</i> , 2021, 23, 33.	2.0	17
43	Recent advances in the regulation of ABCA1 and ABCG1 by lncRNAs. <i>Clinica Chimica Acta</i> , 2021, 516, 100-110.	0.5	19
44	Non-coding RNA crosstalk with nuclear receptors in liver disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166083.	1.8	12
45	miR-33 in cardiometabolic diseases: lessons learned from novel animal models and approaches. <i>EMBO Molecular Medicine</i> , 2021, 13, e12606.	3.3	17
46	Potential Therapeutic Targeting of lncRNAs in Cholesterol Homeostasis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 688546.	1.1	9
47	Vascular Endothelial Senescence: Pathobiological Insights, Emerging Long Noncoding RNA Targets, Challenges and Therapeutic Opportunities. <i>Frontiers in Physiology</i> , 2021, 12, 693067.	1.3	29
48	Emerging Role of Long Non-Coding RNAs in Diabetic Vascular Complications. <i>Frontiers in Endocrinology</i> , 2021, 12, 665811.	1.5	36
49	Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis. <i>Progress in Lipid Research</i> , 2021, 83, 101109.	5.3	86
50	lncRNAs as Therapeutic Targets and Potential Biomarkers for Lipid-Related Diseases. <i>Frontiers in Pharmacology</i> , 2021, 12, 729745.	1.6	8
51	Targeting epigenetics and lncRNAs in liver disease: From mechanisms to therapeutics. <i>Pharmacological Research</i> , 2021, 172, 105846.	3.1	7
52	Non-coding RNAs Related to Lipid Metabolism and Non-alcoholic Fatty Liver Disease. , 2021, , 73-88.		0
53	Long Non-Coding RNAs (lncRNAs) in Cardiovascular Disease Complication of Type 2 Diabetes. <i>Diagnostics</i> , 2021, 11, 145.	1.3	16
54	Novel Long Noncoding RNA, Macrophage Inflammation-Suppressing Transcript (<i>MIST</i>), Regulates Macrophage Activation During Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 914-928.	1.1	32
55	Netrin-1 Alters Adipose Tissue Macrophage Fate and Function in Obesity. <i>Immunometabolism</i> , 2019, 1, .	0.7	41

#	ARTICLE	IF	CITATIONS
56	Functioning of Long Noncoding RNAs Expressed in Macrophage in the Development of Atherosclerosis. <i>Frontiers in Pharmacology</i> , 2020, 11, 567582.	1.6	4
57	“Enhancing” mechanosensing: Enhancers and enhancer-derived long non-coding RNAs in endothelial response to flow. <i>Current Topics in Membranes</i> , 2021, 87, 153-169.	0.5	0
58	Long Non-Coding RNAs in Cardiovascular Diseases: Potential Function as Biomarkers and Therapeutic Targets of Exercise Training. <i>Non-coding RNA</i> , 2021, 7, 65.	1.3	21
59	A lncRNA that regulates cholesterol homeostasis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	0
60	Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma. <i>Non-coding RNA</i> , 2021, 7, 1.	1.3	9
61	Genetics and regulation of HDL metabolism. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159060.	1.2	2
62	Regulatory Non-coding RNAs in Atherosclerosis. <i>Handbook of Experimental Pharmacology</i> , 2020, , 463-492.	0.9	13
65	The Pathogenic Role of Long Non-coding RNA H19 in Atherosclerosis via the miR-146a-5p/ANGPTL4 Pathway. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 770163.	1.1	20
66	HAND2-AS1 targeting miR-1208/SIRT1 axis alleviates foam cell formation in atherosclerosis. <i>International Journal of Cardiology</i> , 2022, 346, 53-61.	0.8	9
68	HDL maturation and remodelling. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159119.	1.2	3
69	Genomic Variants and Multilevel Regulation of ABCA1, ABCG1, and SCARB1 Expression in Atherogenesis. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 170.	0.8	8
70	LncRNAs and Cardiovascular Disease. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1363, 71-95.	0.8	4
71	<i>CASC7</i> : a lncRNA with potential clinical application. <i>International Journal of Radiation Biology</i> , 2022, , 1-9.	1.0	2
72	Pathophysiology of Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3346.	1.8	208
73	Contribution of FBLN5 to Unstable Plaques in Carotid Atherosclerosis via mir128 and mir532“3p Based on Bioinformatics Prediction and Validation. <i>Frontiers in Genetics</i> , 2022, 13, 821650.	1.1	4
74	The Role of Critical N6-Methyladenosine-Related Long Non-Coding RNAs and Their Correlations with Immune Checkpoints in Renal Clear Cell Carcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9773-9787.	0.8	5
75	Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1372, 119-143.	0.8	5
76	Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 889743.	1.1	1

#	ARTICLE	IF	CITATIONS
77	Long noncoding RNAs in cardiometabolic disorders. <i>FEBS Letters</i> , 2022, 596, 1367-1387.	1.3	9
78	Clinical Parameters and Epigenetic Biomarkers of Plaque Vulnerability in Patients with Carotid Stenosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5149.	1.8	10
79	Long non-coding RNA (LncRNA) CHROMR promotes the expression of the CNNM1 gene by adsorbing hsa-miR-1299 to obtain drug resistance in diffuse large B lymphoma cells. <i>Translational Cancer Research</i> , 2022, 11, 1362-1371.	0.4	1
80	A Mutation in Endogenous saRNA miR-23a Influences Granulosa Cells Response to Oxidative Stress. <i>Antioxidants</i> , 2022, 11, 1174.	2.2	5
81	A standardised nomenclature for long non-coding RNAs. <i>IUBMB Life</i> , 2023, 75, 380-389.	1.5	8
82	Signaling by LncRNAs: Structure, Cellular Homeostasis, and Disease Pathology. <i>Cells</i> , 2022, 11, 2517.	1.8	15
83	Long noncoding RNA CHROMR regulates antiviral immunity in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	19
84	Current advancements and future perspectives of long noncoding RNAs in lipid metabolism and signaling. <i>Journal of Advanced Research</i> , 2023, 48, 105-123.	4.4	4
85	Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis. <i>Molecular Therapy</i> , 2022, 30, 3118-3132.	3.7	15
86	RUNX2 stabilization by long non-coding RNAs contributes to hypertrophic changes in human chondrocytes. <i>International Journal of Biological Sciences</i> , 2023, 19, 13-33.	2.6	9
87	Human Macrophage Long Intergenic Noncoding RNA, SIMALR, Suppresses Inflammatory Macrophage Apoptosis via NTN1 (Netrin-1). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2023, 43, 286-299.	1.1	1
88	Long noncoding RNA LEENE promotes angiogenesis and ischemic recovery in diabetes models. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	11
89	Long non-coding RNAs: definitions, functions, challenges and recommendations. <i>Nature Reviews Molecular Cell Biology</i> , 2023, 24, 430-447.	16.1	313
90	Non-coding RNAs in human health and disease: potential function as biomarkers and therapeutic targets. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	39
91	Downregulation of hepatic lncRNA Gm19619 improves gluconeogenesis and lipogenesis following vertical sleeve gastrectomy in mice. <i>Communications Biology</i> , 2023, 6, .	2.0	2
92	MicroRNAs in Macrophages: Regulators of Activation and Function. <i>Journal of Immunology</i> , 2023, 210, 359-368.	0.4	3
93	Is microRNA-33 an Appropriate Target in the Treatment of Atherosclerosis?. <i>Nutrients</i> , 2023, 15, 902.	1.7	3
94	Antisense lncRNA CHROMR is linked to glioma patient survival. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	1

#	ARTICLE	IF	CITATIONS
95	Circulating non-coding RNAs in chronic kidney disease and its complications. Nature Reviews Nephrology, 2023, 19, 573-586.	4.1	5
97	Review article: Type 2 diabetes mellitus: Pathogenesis and therapeutic intervention. AIP Conference Proceedings, 2023, , .	0.3	0